ADAR1 Capital Management »

Upstream Bio shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Upstream Bio (UPB) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Upstream Bio

Tip: Access up to 7 years of quarterly data

All positions including Upstream Bio held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Upstream Bio by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2026-03-31 $315k 35k 9.00
2025-03-31 $92k 15k 6.12

More positions owned by ADAR1 Capital Management

Abivax Sa Sponsored Ads (ABVX)
Protagonist Therapeutics (PTGX)
Roivant Sciences SHS (ROIV)
Immunovant (IMVT)
Terns Pharmaceuticals Call Option (TERN)
State Str Spdr S&p 500 Etf T Tr Unit (SPY)
Cytokinetics Com New (CYTK)
Crinetics Pharmaceuticals In (CRNX)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Denali Therapeutics (DNLI)
Beam Therapeutics (BEAM)
Zai Lab Adr (ZLAB)
Septerna (SEPN)
Vir Biotechnology (VIR)
Dbv Technologies S A Sponsored Ads (DBVT)

View all positions for ADAR1 Capital Management

Top funds holding Upstream Bio

FMR
OrbiMed Advisors
BlackRock
Decheng Capital
Enavate Sciences GP
Vanguard Group
Vanguard Capital Management
Omega Fund Management
State Street Corporation
Y-Intercept
Federated Investors
Geode Capital Management
Millennium Management
Wellington Management Company
SEB Asset Management AB

View all funds holding Upstream Bio